Cibus, Inc. (CBUS) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Cibus, Inc. is an agricultural biotechnology company utilizing proprietary gene editing technology (RTDS) to develop plant traits for major food crops. The company operates as a single reporting segment and is currently in a pre-commercialization phase, relying on collaboration agreements and capital markets for funding. As of May 7, 2025, there were approximately 34.4 million shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $1,034 | $545 |
| Net Loss | $(49,392) | $(26,972) |
| Net Loss Attributable to Cibus, Inc. | $(46,886) | $(23,435) |
| Diluted Net Loss Per Share | $(1.34) | $(1.12) |
| Operating Cash Flow | $(11,827) | $(13,480) |
| Cash and Cash Equivalents (End of Period) | $23,587 | $24,507 |
| Current Liabilities | $21,014 | $19,878 |
| Goodwill Impairment | $20,950 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 90% to $1.0 million, driven by collaboration agreements for Rice and Soybean research.
- Significant Impairment: The company recorded a $21.0 million goodwill impairment charge due to a decline in stock price and a triggering event, compared to no impairment in Q1 2024.
- Expense Fluctuations:
- R&D Expenses: Decreased slightly by 2% to $11.8 million due to cost reduction initiatives.
- SG&A Expenses: Increased 41% to $9.9 million, primarily due to a $3.0 million accrued litigation liability related to a Ninth Circuit Court of Appeals decision regarding insurance proceeds.
- Financing Activity: In January 2025, the company completed a registered direct offering, raising approximately $21.4 million in net proceeds through the issuance of Class A Common Stock and pre-funded warrants.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date. The company expects existing cash to fund operations only into the third quarter of 2025 without additional financing.
- Liquidity Needs: The company must raise additional capital to support operations. Failure to do so may result in significant delays, scaling back, or cessation of operations.
- Restructuring: A restructuring initiative announced in late 2024 included workforce reductions and the planned non-renewal of the San Diego trait development facility lease in August 2025.
- Regulatory Progress: The company reported positive regulatory milestones, including USDA-APHIS designations for Canola traits and approval for field research in California and Ecuador.
- Leadership Change: Rory Riggs resigned as CEO in February 2025; Peter Beetham serves as Interim CEO.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" disclosure and the projection that cash may only last until Q3 2025.
- Litigation Liability: Confirm the status of the $3.0 million accrued liability regarding the Ninth Circuit Court of Appeals decision and potential repayment of insurance proceeds.
- Goodwill Valuation: Review the assumptions used in the $21.0 million goodwill impairment, specifically the 47% discount rate and 3% long-term growth rate.
- Customer Concentration: Note that "Customer A" accounted for 84.1% of Q1 2025 revenue and 84.2% of accounts receivable.
- Warrant Amendments: Understand the impact of the January 2025 warrant amendments (reduced exercise price to $2.50) on future dilution and equity structure.